Article
Real-world Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
2021-03-31
Abstract excerpt
<title>Abstract</title> <p>COVID-19 has spurred much interest in the therapeutic potential of repurposed drugs, such as acid-reducing drugs that act as histamine H2 receptor antagonists (H2RA). These compounds, exemplified by famotidine (e.g., Pepcid) and ranitidine (e.g., Zantac), bind the H2R and block the histamine-triggered stimulation of signal transduction cascades. Histamine and H2RAs, on the one hand, and...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bb59cdf0-bb4d-54b6-a3fa-c3eb8b8d2e1c
- DOI
- 10.21203/rs.3.rs-369927/v1
